Nephrology and Renal Diseases

In-depth clinical trial expertise in renal disease

We have significant experience in the design, planning and execution of Phase I-IV full service global trials in renal diseases. Our nephrology team has in-depth insight into the scientific methodology, competitive research landscape and key regulatory drivers to move product development forward quickly.

Our nephrology/renal disease global investigator network consists of nephrologists, critical care specialists, endocrinologists, internists and key opinion leaders, as well as a broad number of academic sites and dialysis centers that enable us to provide robust feasibility and consulting services across a wide spectrum of renal disease indications.

We recognize that patients with renal disease often face the burden of living with other comorbidities that take a toll on their quality of life and life expectancy. We have developed a comprehensive team of medical experts across various therapeutic areas, including metabolic, cardiovascular and autoimmune, to ensure holistic patient care. This integrated team of medical experts provide our clients with sound strategic guidance to drive efficient and effective clinical trials that address the challenges associated with renal diseases.

Explore the latest industry trends and clinical advancements from leading nephrology experts

0 +


0 +


0 +


Renal and nephrology clinical study experience

Our comprehensive renal and nephrology clinical study experience spans a broad range of indications including:

  • Chronic renal disease and end stage renal disease
  • Diabetic nephropathy
  • Hyperphosphatemia
  • Vasculitis (i.e., SLE)
  • Acute kidney injury
  • Anemia
  • Glomerulonephritis (i.e., IgA nephropathy and focal glomerulosclerosis)
  • Hyperoxaluria
  • Kidney transplantation
  • Polycystic kidney disease
  • Alport syndrome

Additionally, our team has experience working with pediatric and rare renal conditions, having conducted 27 rare renal disease studies over the past five years.

Advancing treatments for CKD and Rare Renal Disorders: Our experts weigh in
Experts address a high unmet need for advancing treatments for rare renal diseases

Advancing renal disease clinical research in peri-and post- approval settings

Our Evidera peri- and post-approval business specializing in evidence, value and access, brings extensive experience across the spectrum of nephrology indications, including chronic kidney disease, diabetic kidney disease, end stage renal disease, renal transplants and renal cell carcinoma. We have completed approximately 150 engagements in nephrology over the past five years across our service offerings and in markets around the globe. This work also includes 22 real-world evidence studies. Our work has addressed a broad range of issues such as treatment sequencing, humanistic and economic burden of disease and epidemiological and market access research. We have also published 70 papers in peer-reviewed and non-peer reviewed journals, such as Immunotherapy, Transplantation, Clinical Therapeutics, the International Journal of Nephrology and the Journal of Clinical Pharmacology.

Partner with a global multi-specialty team in renal disease

Andy Bevan
Executive Director,
Peri- and Post-approval Studies
Carmichael Angeles, MD
Senior Medical Director
Board Certified Nephrologist
Davide Garrisi
Nephrology, GU and
Women’s Health Disease Area Lead
Sarah Dixon Stump
Project Management

If you’re looking to move your product development forward quickly, we can help.